InsiderTrades.com logo
Graham Walmsley net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Graham Walmsley Biography and Net Worth

Director of Akero Therapeutics

Dr. Graham Walmsley is a co-founder and managing partner of Logos Capital, a fundamental biotechnology-focused hedge fund that combines in-house data analytics with scientific and clinical expertise to identify transformative therapies in healthcare. Based in San Francisco, Logos combines expertise across medical, scientific, and statistical disciplines to expand the depth of diligence in identifying compelling investment ideas and uncorrelated-market returns.

Before Logos, Graham was a Principal at Versant Ventures where he invested in biotechnology companies across four funds totaling over $1.5 billion in AUM. While at Versant, he served as a board director, built and launched multiple companies, and was head of business development for Jecure Therapeutics through its acquisition by Roche AG.

Graham has more than 60 scientific publications, and holds an MD and PhD from Stanford University School of Medicine.

How do I contact Graham Walmsley?

The corporate mailing address for Dr. Walmsley and other Akero Therapeutics executives is 170 HARBOR WAY, SOUTH SAN FRANCISCO CA, 94080. Akero Therapeutics can also be reached via phone at (650) 487-6488 and via email at akero@sternir.com. Learn More on Graham Walmsley's contact information.

Has Graham Walmsley been buying or selling shares of Akero Therapeutics?

Graham Walmsley has not been actively trading shares of Akero Therapeutics during the past quarter. Learn More on Graham Walmsley's trading history.

Who are Akero Therapeutics' active insiders?

Akero Therapeutics' insider roster includes Kevin Bitterman (Director), Andrew Cheng (CEO), Tomas Heyman (Director), Patrick Lamy (SVP of Commercial Strategy ), Timothy Rolph (Co-Founder and Chief Scientific Officer), Graham Walmsley (Director), William White (CFO), Catriona Yale (Insider), and Jonathan Young (COO). Learn More on Akero Therapeutics' active insiders.

Are insiders buying or selling shares of Akero Therapeutics?

During the last twelve months, Akero Therapeutics insiders bought shares 3 times. They purchased a total of 341,309 shares worth more than $15,863,577.75. During the last twelve months, insiders at the sold shares 57 times. They sold a total of 964,114 shares worth more than $33,147,324.75. The most recent insider tranaction occured on March, 27th when Director G. Walmsley Graham bought 50,000 shares worth more than $2,177,500.00. Insiders at Akero Therapeutics own 7.9% of the company. Learn More about insider trades at Akero Therapeutics.

Information on this page was last updated on 3/27/2025.

Graham Walmsley Insider Trading History at Akero Therapeutics

See Full Table

Graham Walmsley Buying and Selling Activity at Akero Therapeutics

This chart shows G. Walmsley Graham's buying and selling at Akero Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$10M$0$10MTotal Insider BuyingTotal Insider Selling

Akero Therapeutics Company Overview

Akero Therapeutics logo
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $36.73
Low: $36.69
High: $39.99

50 Day Range

MA: $47.41
Low: $36.73
High: $57.56

2 Week Range

Now: $36.73
Low: $17.86
High: $58.40

Volume

1,541,126 shs

Average Volume

830,954 shs

Market Capitalization

$2.92 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A